Showing 1801-1810 of 3314 results for "".
- Horizon Therapeutics Trading Halted Today; FDA Committee Meeting to Discuss Teprotumumab for Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-trading-halted-today-fda-committee-meeting-to-discuss-teprotumumab-for-thyroid-eye-disease/2477167/Horizon Therapeutics announced that NASDAQ has halted trading of the company’s common stock, listed as HZNP. As per the FDA guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is holding a meeting today from 8 am to 4 pm ET to discuss
- Prevent Blindness Focus On Eye Health National Summithttps://modernod.com/news/prevent-blindness-focus-on-eye-health-national-summit/2476719/Prevent Blindness will host the 8th Annual Focus on Eye Health National Summit at the National Press Club in Washington DC on Wednesday, July 17 at 7:30 am ET. The theme of the event is “A Lifetime of Vision” and will feature keynote speaker Bill Barkley, deaf-blind adventure
- CoFi Announces Market-Wide Availability of its Multi-Provider Financing Solution with CareCredithttps://modernod.com/news/cofi-announces-market-wide-availability-of-its-multi-provider-financing-solution-with-carecredit/2482133/CoFi announced that patient payments with the CareCredit credit card can now be processed through CoFi’s multi-party payments platform. This market-wide availability follows a successful beta period involving joint CoFi and CareCredit customers. “We’ve
- Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitishttps://modernod.com/news/tarsus-completes-enrollment-for-the-pivotal-phase-3-saturn-2-trial-of-tp-03-to-treat-demodex-blepharitis/2480610/Tarsus Pharmaceuticals announced it has completed enrollment of Saturn-2, the company’s second pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with Demodex blepharitis and executed a $175 million credit facility with Hercules Capital and Silicon
- FocalPoint Holdings Partners with GreenSky Patient Solutions to Enable 8,000 Ophthalmology Providers to Provide Patient Financinghttps://modernod.com/news/focalpoint-holdings-partners-with-greensky-patient-solutions-to-enable-8000-ophthalmology-providers-to-provide-patient-financing/2477162/FocalPoint Holdings announced a partnership with GreenSky Patient Solutions which enables FocalPoint Holdings’ network of 8,000 ophthalmology and optometry providers to offer flexible financing solutions, including revolving credit and installment loan products. “As the healthcare system i
- Ocular Therapeutix Announces Completion of Debt Refinancinghttps://modernod.com/news/ocular-therapeutix-announces-completion-of-debt-refinancing/2476236/Ocular Therapeutix announced that it has closed a refinancing of its existing debt by entering into a new $25 million term loan with MidCap Financial and Silicon Valley Bank. The 5-year term loan facility allows for an expansion of the company’s prior $18 million credit facility to $25 mil
- Everest Medicines Acquires Greater China Rights to Lenz Therapeutics’ Presbyopia Eye Drop Vizzhttps://modernod.com/news/everest-medicines-acquires-greater-china-rights-to-lenz-therapeutics-presbyopia-eye-drop-vizz/2487383/Key Takeaways Everest Medicines acquired Greater China rights to Lenz Therapeutics’ presbyopia treatment Vizz (LNZ100) from Corxel Pharmaceuticals
- The Vision Council Opens Registration for 2026 Lab Leadership Forum in Las Vegashttps://modernod.com/news/the-vision-council-opens-registration-for-2026-lab-leadership-forum-in-las-vegas/2487132/The Vision Council has opened registration for the 2026 Lab Leadership Forum, the organization’s flagship event for optical lab professionals, scheduled for Sept. 16-18, 2026, at the M Resort Spa Casino in Las Vegas. The annual
- SightGlass Vision Reports on 2-Year Chinese Study for DOT Spectacle Lenses for Myopiahttps://modernod.com/news/sightglass-vision-reports-on-2-year-chinese-study-for-dot-spectacle-lenses-for-myopia/2486985/Key Takeaways SightGlass Vision’s DOT spectacle lenses reduced myopia progression by more than 1D on average after 2 years in Chinese children aged 6 to 10
- BostonSight Expands Scleral Lens Portfolio with New Smaller Diameter Optionshttps://modernod.com/news/bostonsight-expands-scleral-lens-portfolio-with-new-smaller-diameter-options/2486629/Key Takeaways BostonSight introduced three new smaller BostonSight Scleral lens diameters available in a single FitKit for both eyes